23.34
Schlusskurs vom Vortag:
$22.29
Offen:
$22.48
24-Stunden-Volumen:
4.12M
Relative Volume:
1.15
Marktkapitalisierung:
$17.34B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-23.17
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
+13.91%
1M Leistung:
+20.03%
6M Leistung:
+40.26%
1J Leistung:
+18.54%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SMMT
Summit Therapeutics Inc
|
23.34 | 16.56B | 220.00K | -746.08M | -211.81M | -1.0074 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-17 | Eingeleitet | Barclays | Underweight |
2025-09-04 | Eingeleitet | Guggenheim | Buy |
2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
2025-07-01 | Eingeleitet | UBS | Buy |
2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
2025-02-28 | Eingeleitet | Goldman | Buy |
2025-01-08 | Eingeleitet | Truist | Buy |
2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
2024-12-06 | Eingeleitet | Jefferies | Buy |
2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
2024-05-07 | Eingeleitet | Citigroup | Buy |
2024-03-26 | Eingeleitet | Stifel | Buy |
2018-06-28 | Herabstufung | Janney | Buy → Neutral |
2018-05-02 | Eingeleitet | Janney | Buy |
2018-04-12 | Bestätigt | Needham | Buy |
2018-02-13 | Eingeleitet | BTIG Research | Buy |
2018-01-04 | Eingeleitet | SunTrust | Buy |
2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
2016-10-05 | Bestätigt | Needham | Buy |
2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
2015-03-30 | Eingeleitet | Needham | Buy |
2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance
Public Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
How to use Fibonacci retracement on Summit Therapeutics Inc.Gap Up & Community Verified Trade Signals - newser.com
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
Published on: 2025-10-05 07:31:28 - newser.com
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Market Sentiment & Community Driven Trade Alerts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - Eastern Progress
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo
Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Summit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Published on: 2025-09-30 03:00:28 - newser.com
Published on: 2025-09-30 00:09:58 - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in
Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus
Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan
Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World
Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Rockland Trust Co. Takes $8.51 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN
Wealth Management Partners LLC Sells 20,671 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):